ArticleThe oncologist2012
Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer.
Article in The oncologist, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.The Cochrane database of systematic reviews · 2021Pooled it
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.The Cochrane database of systematic reviews · 2017Pooled it
- Slow versus fast subcutaneous heparin injections for prevention of bruising and site pain intensity.The Cochrane database of systematic reviews · 2017Pooled it
- CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients.BMC cancer · 2013Trial
- Development and validation of thromboembolism diagnostic algorithms in children with cancer from real-world data.Pediatric research · 2024Article
- Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study.Journal of thrombosis and thrombolysis · 2022Observational
- Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism.Journal of thrombosis and thrombolysis · 2021Article
- Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review.Current treatment options in cardiovascular medicine · 2019Review
- Duration of anticoagulant therapy and VTE recurrence in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Review
- Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid.Current oncology reports · 2019Review
- Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.American journal of hematology · 2018Observational
- Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.Research and practice in thrombosis and haemostasis · 2017Article
- Review
- Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Article
- Article
- Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?PloS one · 2015Article
- Implementing thrombosis guidelines in cancer patients: a review.Rambam Maimonides medical journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundEvidence-based treatment guidelines recommend low molecular weight heparin (LMWH) monotherapy for cancer-associated venous thromboembolism (VTE). This analysis assessed the first-line treatment strategies for VTE in patients with advanced solid tumors.
methodsUsing administrative data from advanced lung, prostate, colon, or breast cancer patients diagnosed between January 2000 and December 2007 at four HMOs with integrated delivery systems, patients with an inpatient or outpatient VTE diagnosed within 2 years after cancer diagnosis and an outpatient purchase of warfarin, LMWH, and/or fondaparinux anticoagulant within 7 days of the VTE diagnosis were identified. First-line outpatient VTE pharmacological treatment and factors independently associated with receipt/non-receipt of LMWH monotherapy were assessed.
resultsOverall, 25% of the 1,089 eligible patients received LMWH monotherapy as primary VTE treatment. The percentage increased steadily over time from 18% among patients diagnosed in 2000 to 31% among those diagnosed in 2007. Factors associated with LMWH monotherapy included VTE diagnosis year, chemotherapy within 60 days prior to VTE diagnosis, history of VTE prior to cancer diagnosis, and invasive surgery in the 90 days following VTE diagnosis. Colorectal and prostate cancer patients versus lung cancer patients and stage III versus stage IV patients were less likely to be treated with LMWH monotherapy.
conclusionsAdoption of LMWH monotherapy as initial treatment for cancer-associated VTE was low but increased steadily over the study period. Future studies should explore reasons underlying the underutilization of this preferred evidence-based treatment as well as the comparative effectiveness of LMWH versus warfarin-based anticoagulation in real-world cancer patients with VTE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.